

## **Lodgement of Medicinal Cannabis License Application with the Department of Health**

Impression Healthcare Limited ('IHL') is pleased to announce that it has successfully completed the pre-license stage and accordingly has lodged an application for a licence to possess and supply scheduled substances, including cannabinoid medicines, with the Department of Health, Victoria, on 11<sup>th</sup> December, 2018.

Today's announcement is in line with previous announcements dated, 23<sup>rd</sup> September, 24<sup>th</sup> October and 4<sup>th</sup> December, 2018, in which the Company outlined its collaboration and licence agreements with AXIM Biotechnologies and Resolution Chemicals and its intention to complete the pre-licence application processes needed to meet the stringent requirements of the Australian authorities.

According to IHL's pharmaceutical application consultants, if approved, the license should be issued within 8 weeks.

Once a license is issued, IHL can:

- Sell approved cannabinoid medicines throughout Australia, where the law permits, under the Special Access Scheme and through the Authorised Prescriber Network.
- Import and Export cannabinoid medicines to and from Australia.

In order to get to this point, IHL completed extensive risk and security protocol reviews and implemented the processes required for license approval, including making arrangements with 3<sup>rd</sup> party suppliers where necessary.

Yesterday's application lodgement represents an important milestone in IHL's strategy to become a leading player in the cannabinoid based medicine market by leveraging the intellectual property of existing market leaders.

To date, IHL has executed licence agreements with AXIM Biotechnologies (USA) and Resolution Chemicals (UK), both leading lights in the emerging cannabinoid based medicine field.

**ENDS**



Date: 12 December 2018  
ASX Announcement (ASX: IHL)

### **About Impression Healthcare Limited (ASX: IHL)**

Impression Healthcare Limited is Australia's largest home dental impression company and is disrupting the dental devices market by providing consumers with an in-home method to consume laboratory-grade and personalised dental healthcare products at significantly lower prices than those offered by the traditional dental industry. Impression has significantly grown its distribution footprint and increased its revenues by 359% in the 2018 Financial Year. With its own dental laboratory in Victoria, Australia Impression offers best in class teeth protection and helps its customers combat bruxism, snoring, mild to moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression is broadening its commitment to disruption in the healthcare sector by exploring opportunities in medicinal cannabis distribution and development, underpinned by a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Inc. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids for a wide range of indications. Impression will leverage its oral health marketing activities to explore opportunities distribute a range of AXIM's over the counter and therapeutic products as public opinion of cannabinoid-based therapeutics steadily improves.

**Investors:** [investors@impression.healthcare](mailto:investors@impression.healthcare)

**Website:** [www.impression.healthcare](http://www.impression.healthcare)